The mRNA expression and survival months for GADD45A in tumor tissues were obtained from 877 RCC patients in the TCGA database, as shown in Figure 4B. As shown in Figure 4B, Kaplan–Meier survival analysis demonstrated that the 5-year survival rate of RCC patients with higher GADD45A tumor expression (79% of the 5-year survival rate) was significantly better than that of patients with low expression (63% of the 5-year survival rate, p < 0.001). The gene discussed is GADD45A; the disease is renal cell carcinoma.